NCT06537297View on ClinicalTrials.gov

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

April 30, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab

"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."

Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT06537297 - Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | Biotech Hunter | Biotech Hunter